Teva 3rd-quarter net up 2.9%, sales up 25%

flagship drug, the multiple-sclerosis treatment Copaxone, rose 38% in the quarter to $776 million. Sales of Azilect for Parkinson's disease rose 39% to $64 million. At Oct. 23, Teva had 210 product applications awaiting final clearance by the U.S. Food...